Announcements Trials
Browse Landscape

Phase

Phase 2 25Phase 3 15Phase 1 12Phase NA 4Phase EARLY_PHASE1 2Phase 2/3 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma 6Leukemia 6Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Non-Hodgkin 4Recurrence 3Sezary Syndrome 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Follicular 2Leukemia, T-Cell 2Leukemia, Myeloid, Acute 2Leukemia, Biphenotypic, Acute 2Congenital Abnormalities 2Waldenstrom Macroglobulinemia 1Thrombocythemia, Essential 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Teratoma 1Small Cell Lung Carcinoma 1Seminoma 1Sarcoma, Ewing 1Retinoblastoma 1Primary Myelofibrosis 1Polycythemia Vera 1Neuroblastoma 1Neoplasms 1Myeloproliferative Disorders 1

Interventions

omburtamab I-131 1capmatinib 1alectinib 1Melphalan 1Etoposide 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Neuroblastoma × Etoposide × Clear all
NCT00539500 2019-07-26

Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma

M.D. Anderson Cancer Center

Phase 2/3 Terminated
3 enrolled 4 charts
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡